Development stage healthcare delivery company HOPE Therapeutics Inc, a subsidiary of NRx Pharmaceuticals Inc (Nasdaq:NRXP), announced on Monday that it has appointed BTIG, a financial services company specialising in investment banking, institutional trading, research and related brokerage services, as its financial advisor.
The scope of the engagement includes advisory and assistance in evaluating strategic and financing options available to the company and identification, evaluation and negotiation of potential acquisition targets for the HOPE network of clinics, as well as equity and debt financing structures.
The company recently announced execution of an agreement for USD27m in funding for HOPE clinic acquisition. Upon closing of the first tranche of the anticipated financing, the company intends to leverage the investment with proposed bank debt and similar instruments to fund its initial rollup of Interventional Psychiatry Clinics.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
ContextVision partners with University of Washington to advance liver disease diagnostics
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
hVIVO to conduct RSV human challenge trial for Inhalon Biopharma
Moberg Pharma and Allderma announce launch of Terclara in Norway
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan